FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer

被引：0
|
作者：
Shao Zhimin
Fan, Lei
Ma Linxiaoxi
Wu, Songyang
Chen, Li
Liu, Xiyu
Zhang, Wenjuan
Hu, Xin
Jiang, Yizhou
Wang, Zhonghua
Li, Huajun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[4] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
    Yin Liu
    Xiu-Zhi Zhu
    Yi Xiao
    Song-Yang Wu
    Wen-Jia Zuo
    Qiang Yu
    A-Yong Cao
    Jun-Jie Li
    Ke-Da Yu
    Guang-Yu Liu
    Jiong Wu
    Tao Sun
    Jiu-Wei Cui
    Zheng Lv
    Hui-Ping Li
    Xiao-Yu Zhu
    Yi-Zhou Jiang
    Zhong-Hua Wang
    Zhi-Ming Shao
    Cell Research, 2023, 33 : 389 - 402
  • [2] Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
    Liu, Yin
    Zhu, Xiu-Zhi
    Xiao, Yi
    Wu, Song-Yang
    Zuo, Wen-Jia
    Yu, Qiang
    Cao, A-Yong
    Li, Jun-Jie
    Yu, Ke-Da
    Liu, Guang-Yu
    Wu, Jiong
    Sun, Tao
    Cui, Jiu-Wei
    Lv, Zheng
    Li, Hui-Ping
    Zhu, Xiao-Yu
    Jiang, Yi-Zhou
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CELL RESEARCH, 2023, 33 (05) : 389 - 402
  • [3] Optimising first-line subtyping-based therapy in triplenegative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
    Fan, Lei
    Wang, Zhong-Hua
    Ma, Lin-Xiaoxi
    Wu, Song-Yang
    Wu, Jiong
    Yu, Ke-Da
    Sui, Xin-Yi
    Xu, Ying
    Liu, Xi-Yu
    Chen, Li
    Zhang, Wen -Juan
    Jin, Xi
    Xiao, Qin
    Shui, Ruo-Hong
    Xiao, Yi
    Wang, Han
    Yang, Yun-Song
    Huang, Xiao-Yan
    Cao, A-Yong
    Li, Jun-Jie
    Di, Gen -Hong
    Liu, Guang-Yu
    Yang, Wen-Tao
    Hu, Xin
    Xia, Yan
    Liang, Qian-Nan
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    LANCET ONCOLOGY, 2024, 25 (02): : 184 - 197
  • [4] Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial
    Shao, Zhi-Ming
    Wang, Zhong-Hua
    Jiang, Yi-Zhou
    Liu, Yin
    Zhu, Xiu-Zhi
    Xiao, Yi
    Wu, Song-Yang
    Zuo, Wen-Jia
    Yu, Qiang
    Cao, A-Yong
    Li, Jun-Jie
    Yu, Ke-Da
    Liu, Guang-Yu
    Wu, Jiong
    Sun, Tao
    Cui, Jiuwei
    Lv, Zheng
    Li, Hui-Ping
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
    Montagna, Emilia
    Bagnardi, Vincenzo
    Cancello, Giuseppe
    Sangalli, Claudia
    Pagan, Eleonora
    Iorfida, Monica
    Mazza, Manuelita
    Mazzarol, Giovanni
    Dellapasqua, Silvia
    Munzone, Elisabetta
    Goldhirsch, Aaron
    Colleoni, Marco
    BREAST CARE, 2018, 13 (03) : 177 - 181
  • [6] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Wang, Biyun
    Sun, Tao
    Zhao, Yannan
    Wang, Shusen
    Zhang, Jian
    Wang, Zhonghua
    Teng, Yue-E
    Cai, Li
    Yan, Min
    Wang, Xiaojia
    Jiang, Zefei
    Pan, Yueyin
    Luo, Jianfeng
    Shao, Zhimin
    Wu, Jiong
    Guo, Xiaomao
    Hu, Xichun
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Biyun Wang
    Tao Sun
    Yannan Zhao
    Shusen Wang
    Jian Zhang
    Zhonghua Wang
    Yue-E Teng
    Li Cai
    Min Yan
    Xiaojia Wang
    Zefei Jiang
    Yueyin Pan
    Jianfeng Luo
    Zhimin Shao
    Jiong Wu
    Xiaomao Guo
    Xichun Hu
    Nature Communications, 13
  • [8] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Zhao, Mingchuan
    Miao, Haitao
    Jin, Juan
    Hu, Xichun
    Wang, Biyun
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
    Tredan, Olivier
    Campone, Mario
    Jassem, Jacek
    Vyzula, Rostislav
    Coudert, Bruno
    Pacilio, Carmen
    Prausova, Jana
    Hardy-Bessard, Anne-Claire
    Arance, Ana
    Mukhopadhyay, Pralay
    Aloe, Alessandra
    Roche, Henri
    CLINICAL BREAST CANCER, 2015, 15 (01) : 8 - 15
  • [10] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
    Schmid, Peter
    Cortes, Javier
    Robson, Mark
    Iwata, Hiroji
    Hegg, Roberto
    Verma, Sunil
    Nechaeva, Marina
    Xu, Binghe
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    CANCER RESEARCH, 2020, 80 (04)
12345